Elicio Therapeutics, Inc. Debt Conversion, Converted Instrument, Amount
Elicio Therapeutics, Inc. (ELTX) reported Debt Conversion, Converted Instrument, Amount of $1.41 million for the 9-month period ending 2020-09-30, per its 10-Q filed 2021-11-12.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2021-11-12
- 2020-09-30: Debt Conversion, Converted Instrument, Amount 9 month $1.41M.
| Period end | Debt Conversion, Converted Instrument, Amount 9 month |
|---|---|
| 2020-09-30 | $1.41M 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |